^
Association details:
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Source:
Title:

MP18-18: P53 is involved in resistance to sunitinib in renal cell carcinoma

Published date:
05/15/2020
Excerpt:
 Additionally, we investigated the expression of P53 in 52 ccRCC cases treated with sunitinib treatment. A Kaplan-Meier analysis showed that the positive cases of P53 were associated with poor prognosis after sunitinib treatment (P = 0.04)
Evidence Level:
Resistant: D – Preclinical
Source:
Title:

MP18-18: P53 is involved in resistance to sunitinib in renal cell carcinoma

Published date:
05/15/2020
Excerpt:
...the expression of P53 was decreased in sunitinib resistant cells compared with that in parental cells...The expression of P53 was downregulated in sunitinib resistant RCC cell lines.